|
|
News Breaks
|
November 12, 2009
|
| 10:51 EDT |  | ELN |
| theflyonthewall.com: | Elan Corp volatility flat at 73 on renewed takeover chatter | | Elan is recently up 14c to $6.50 on renewed takeover chatter. Call option volume of 5,137 contracts compares to put volume of 342 contracts. November and December option implied volatility of 73 is near its 26-week average of 74, according to Track Data, suggesting non-directional price movement. :theflyonthewall.com |
|
|
News For ELN From The Last 14 Days Check below for free stories on ELN the last two weeks.
There are 7 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 9, 2012
|
| 06:58 EDT |  | ELN |
| theflyonthewall.com: | Elan downgraded to Neutral from Outperform at Credit Suisse | | Credit Suisse downgraded Elan citing valuation. Note that Exane BNP Paribas upgraded shares this morning. :theflyonthewall.com |
| | 06:07 EDT |  | ELN |
|
|
February 8, 2012
|
| 05:57 EDT |  | ELN |
| theflyonthewall.com: | Elan sees 2012 revenue $1.2B-$1.25B vs. consensus $1.26B | | Sees 2012 adjusted EBITDA of greater than $200M. :theflyonthewall.com |
| | 05:56 EDT | | ELN |
|
|
February 6, 2012
|
| 05:27 EDT |  | ELN |
|
|
January 26, 2012
|
| 08:03 EDT | | ELN |
| theflyonthewall.com: | Biogen, Elan announce Phase 3b ASCEND trial for TYSABRI | | Biogen Idec (BIIB) and Elan Corporation (ELN) announced a global Phase 3b study, ASCEND, that is being conducted to evaluate the effectiveness of TYSABRI as a treatment for secondary-progressive multiple sclerosis. A global study, ASCEND is expected to enroll approximately 850 patients in 15 countries. The primary endpoint is to investigate whether treatment with TYSABRI slows the accumulation of disability not related to relapses in subjects with SPMS. :theflyonthewall.com |
| | 07:28 EDT |  | ELN |
| theflyonthewall.com: | J&J could make cash offer for Elan sparked by Roche/Illumina, Daily Mail says | | Following Roche's (RHHBY) bid for Illumina (ILMN), rumors are swirling that Johnson & Johnson (JNJ) could pounce on Elan (ELN) with a "knock-out" cash offer, the Daily Mail reports. Johnson & Johnson holds an 18% stake in Elan. Reference Link :theflyonthewall.com |
|
|
|
|
|
Subscribe for More Information